Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II seamless study of EN002 topical gel in non-melanoma skin cancer and precancerous skin lesions
CTR20221021Phase 2Active
- Sponsor
- Enkang Pharmaceutical (Guangzhou) Co., Ltd.
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EN002-gel in non-melanoma skin cancer (NMSC), cutaneous premalignancy, actinic keratosis (AK), Bowen disease (BD), basal cell carcinoma (BCC), sponsored by Enkang Pharmaceutical (Guangzhou) Co., Ltd.. Started Sep 2022; status: active.
02
Drugs
EN002-gel
03
Conditions
non-melanoma skin cancer (NMSC)cutaneous premalignancyactinic keratosis (AK)Bowen disease (BD)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on CTR20221021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221021.